

eAppendix 1. AAN Guidelines Subcommittee mission

The mission of the Guidelines Subcommittee is to develop, disseminate, and implement evidence-based systematic reviews and clinical practice guidelines related to the causation, diagnosis, treatment, and prognosis of neurologic disorders. The Guidelines Subcommittee is committed to using the most rigorous methods available within its budget, in collaboration with other available AAN resources, to efficiently accomplish this mission.

eAppendix 2. AAN Guidelines Subcommittee members 2021-2023

Alexander Rae-Grant, MD (Chair), John J. Halperin, MD (Vice-Chair), Matthew Bradford Bevers, MD, Lori L. Billingham, MD, Kelsey Cacic, MD, James Dorman, MD, Wendy S. Edlund, MD, Brittany Jade Farro, MSPAS, PA-C, Gary S. Gronseth, MD, FAAN, Le Hua, MD, Koto Ishida, MD, Mark Douglas Johnson, MD, Charles Kassardjian, MD, Mark Robert Keezer, MD, PhD, K.H. Vincent Lau, MD, Mia T. Minen, MD, Alison M. Pack, MD, Sonja Potrebic, MD, PhD, James J. Reese, Jr., MD, MPH, Vishwanath Sagi, MD, Navdeep Sangha, MD, Nikolaos Scarmeas, MD, Nirranjan N. Singh, MD, Sarah Tanveer, Benjamin D. Tolchin, MD, Shawniqua T. Williams Roberson, MD, Shuhan Zhu, MD

eAppendix 3. Results of pragmatic systematic review (original & updated)

Reference	Search	Include?	Exclude?
Loureiro JC, et al. Passive anti-amyloid immunotherapy for Alzheimer's disease. <i>Curr Opin Psychiatry</i> 2020;33:284-291.	Original	No	Yes; review article
Chiao P, et al. Impact of reference and target region selection on amyloid PET SUV ratios in the Phase 1b PRIME study of aducanumab. <i>J Nucl Med</i> 2019;60:100-106.	Original	Yes	No
Ferrero J, et al. First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer's disease. <i>Alzheimers Dement</i> 2016;2:169-176.	Original	Yes	No
Sevigny J, et al. The antibody aducanumab reduces beta-amyloid	From reference lists	Yes	No

<p>plaques in Alzheimer’s disease. Nature. 2016;537:50–56.</p>			
<p>Sevigny J, et al. Amyloid PET screening for enrichment of early-stage Alzheimer disease clinical trials: experience in a Phase 1b clinical trial. Alzheimer Dis Assoc Disord 2016;30:1-7.</p>	Original	No	Yes; manuscript reports on screening for study; study results are not included
<p>Salloway S, et al. Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early Alzheimer disease. JAMA Neurol 2021; online ahead of print. doi: 10.1001/jamaneurol.2021.4161.</p>	Update	Yes	No
<p>Shintani A. Biostatistical methods for understanding the principle of randomized controlled trials. Brain Nerve 2021;73:999-1006.</p>	Update	No	Yes; review